Share Price and Basic Stock Data
Last Updated: November 20, 2025, 9:03 pm
| PEG Ratio | -1.55 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Wanbury Ltd, operating in the pharmaceutical sector, reported a share price of ₹230 and a market capitalization of ₹805 Cr. The company’s revenue from operations has shown a positive trajectory, recording sales of ₹485 Cr in the fiscal year ending March 2023, which rose to ₹578 Cr in March 2024, and is expected to reach ₹600 Cr by March 2025. The quarterly sales figures reflect this growth trend, with the most recent quarter (June 2024) reporting sales of ₹131 Cr, compared to ₹126 Cr in December 2023 and ₹133 Cr in March 2024. This consistent increase in revenue underscores Wanbury’s ability to expand its market share and enhance its product offerings, positioning itself favorably within the competitive pharmaceutical landscape.
Profitability and Efficiency Metrics
Wanbury Ltd’s profitability metrics demonstrate significant improvements, with a reported net profit of ₹31 Cr for the fiscal year ending March 2025, up from ₹56 Cr in March 2024. The operating profit margin (OPM) stood at 13.31% for the same period, reflecting a steady increase from 4.82% in March 2023. The company’s return on equity (ROE) is particularly noteworthy at 76.5%, indicating effective utilization of shareholder capital. Moreover, Wanbury’s cash conversion cycle (CCC) was recorded at -55 days, highlighting its efficiency in managing receivables and inventory. This efficiency, coupled with a strong interest coverage ratio of 2.16x, suggests that the company is well-positioned to meet its financial obligations while generating profit.
Balance Sheet Strength and Financial Ratios
Wanbury Ltd’s balance sheet reflects robust financial health, with no reported borrowings and a significant return on capital employed (ROCE) of 36.7%. The company’s price-to-book value ratio (P/BV) stood at 12.97x, indicating a premium valuation compared to its book value of ₹18.09 per share as of March 2025. The interest coverage ratio of 2.16x further emphasizes the firm’s ability to manage its debt levels effectively. Additionally, the current ratio of 1.11x suggests that the company possesses sufficient short-term assets to cover its liabilities, which is a positive indicator for liquidity. Overall, these financial ratios illustrate a well-managed company with a solid capital structure and strong profitability potential.
Shareholding Pattern and Investor Confidence
As of June 2025, Wanbury Ltd’s shareholding pattern reveals that promoters hold 39.63% of the equity, demonstrating a stable ownership structure. The public holds a significant 59.55%, while foreign institutional investors (FIIs) have increased their stake to 1.59%, indicating growing confidence in the company’s prospects. The number of shareholders has also risen to 17,774, which reflects increasing retail investor interest. This diverse ownership structure is beneficial for maintaining stability and fostering investor confidence, particularly as the company continues to report strong financial performance. However, the lack of substantial institutional investment could pose a risk in terms of stock price volatility.
Outlook, Risks, and Final Insight
Looking ahead, Wanbury Ltd is positioned for growth, driven by its improving profitability and operational efficiency. However, risks remain, including potential fluctuations in raw material prices and regulatory challenges in the pharmaceutical sector. The company’s dependence on the domestic market could limit its growth if economic conditions deteriorate. Nevertheless, Wanbury’s strong financial metrics and improving sales trajectory suggest that it can navigate these challenges effectively. The company may also benefit from strategic partnerships or expansion into new markets to enhance growth prospects. Overall, Wanbury Ltd presents a compelling investment opportunity, albeit with caution advised regarding external market factors.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Wanbury Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 159 Cr. | 127 | 247/84.3 | 35.2 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.52 Cr. | 1.84 | 4.33/1.82 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,612 Cr. | 423 | 479/192 | 95.5 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.0 Cr. | 43.1 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 38.2 Cr. | 26.1 | 29.1/17.0 | 91.1 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,228.23 Cr | 1,183.75 | 53.16 | 202.47 | 0.35% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 117 | 124 | 126 | 133 | 146 | 144 | 146 | 139 | 131 | 161 | 133 | 172 | 163 |
| Expenses | 120 | 118 | 119 | 119 | 133 | 127 | 124 | 121 | 120 | 141 | 120 | 142 | 139 |
| Operating Profit | -3 | 6 | 6 | 14 | 13 | 17 | 21 | 18 | 11 | 20 | 14 | 30 | 24 |
| OPM % | -3% | 5% | 5% | 11% | 9% | 12% | 15% | 13% | 8% | 12% | 10% | 17% | 15% |
| Other Income | 2 | 1 | 0 | -3 | 1 | 1 | 1 | 26 | 1 | 2 | 1 | 2 | 0 |
| Interest | 3 | 4 | 7 | 8 | 6 | 8 | 8 | 7 | 8 | 10 | 10 | 9 | 8 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 |
| Profit before tax | -7 | -1 | -3 | 1 | 5 | 7 | 10 | 34 | 1 | 8 | 1 | 19 | 14 |
| Tax % | -3% | 25% | 8% | -11% | 6% | -2% | -0% | 1% | 0% | 2% | 5% | -6% | 1% |
| Net Profit | -7 | -1 | -3 | 1 | 5 | 7 | 10 | 34 | 1 | 8 | 1 | 20 | 13 |
| EPS in Rs | -2.21 | -0.27 | -1.00 | 0.31 | 1.43 | 2.25 | 3.14 | 10.27 | 0.32 | 2.45 | 0.37 | 6.18 | 4.10 |
Last Updated: August 20, 2025, 1:15 am
Below is a detailed analysis of the quarterly data for Wanbury Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 163.00 Cr.. The value appears to be declining and may need further review. It has decreased from 172.00 Cr. (Mar 2025) to 163.00 Cr., marking a decrease of 9.00 Cr..
- For Expenses, as of Jun 2025, the value is 139.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 142.00 Cr. (Mar 2025) to 139.00 Cr., marking a decrease of 3.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 24.00 Cr.. The value appears to be declining and may need further review. It has decreased from 30.00 Cr. (Mar 2025) to 24.00 Cr., marking a decrease of 6.00 Cr..
- For OPM %, as of Jun 2025, the value is 15.00%. The value appears to be declining and may need further review. It has decreased from 17.00% (Mar 2025) to 15.00%, marking a decrease of 2.00%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 2.00 Cr..
- For Interest, as of Jun 2025, the value is 8.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 9.00 Cr. (Mar 2025) to 8.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 4.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.00 Cr. (Mar 2025) to 4.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 19.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 5.00 Cr..
- For Tax %, as of Jun 2025, the value is 1.00%. The value appears to be increasing, which may not be favorable. It has increased from -6.00% (Mar 2025) to 1.00%, marking an increase of 7.00%.
- For Net Profit, as of Jun 2025, the value is 13.00 Cr.. The value appears to be declining and may need further review. It has decreased from 20.00 Cr. (Mar 2025) to 13.00 Cr., marking a decrease of 7.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 4.10. The value appears to be declining and may need further review. It has decreased from 6.18 (Mar 2025) to 4.10, marking a decrease of 2.08.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:08 am
| Metric | Sep 2014n n 18m | Mar 2015n n 6m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 661 | 250 | 420 | 432 | 370 | 391 | 367 | 392 | 511 | 485 | 578 | 600 | 630 |
| Expenses | 637 | 228 | 387 | 414 | 438 | 375 | 344 | 374 | 475 | 459 | 503 | 520 | 542 |
| Operating Profit | 25 | 21 | 33 | 19 | -68 | 16 | 23 | 18 | 36 | 26 | 75 | 80 | 88 |
| OPM % | 4% | 9% | 8% | 4% | -18% | 4% | 6% | 5% | 7% | 5% | 13% | 13% | 14% |
| Other Income | -78 | 6 | 0 | 90 | 76 | 9 | 84 | 2 | 77 | -3 | 24 | -0 | 5 |
| Interest | 48 | 19 | 32 | 36 | 31 | 40 | 33 | 23 | 21 | 21 | 29 | 37 | 37 |
| Depreciation | 23 | 5 | 9 | 10 | 10 | 10 | 10 | 10 | 11 | 12 | 13 | 13 | 14 |
| Profit before tax | -125 | 4 | -7 | 62 | -32 | -25 | 65 | -12 | 81 | -10 | 56 | 30 | 42 |
| Tax % | 2% | 28% | 0% | 1% | -1% | -1% | 0% | 2% | -0% | 1% | 1% | -3% | |
| Net Profit | -128 | 3 | -7 | 62 | -32 | -25 | 64 | -13 | 81 | -10 | 56 | 31 | 43 |
| EPS in Rs | -63.95 | 1.60 | -3.58 | 26.71 | -13.49 | -10.48 | 25.79 | -5.04 | 24.94 | -3.18 | 17.09 | 9.32 | 13.10 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 985.71% | -151.61% | 21.88% | 356.00% | -120.31% | 723.08% | -112.35% | 660.00% | -44.64% |
| Change in YoY Net Profit Growth (%) | 0.00% | -1137.33% | 173.49% | 334.12% | -476.31% | 843.39% | -835.42% | 772.35% | -704.64% |
Wanbury Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 10% |
| 3 Years: | 5% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 30% |
| 3 Years: | 75% |
| TTM: | 60% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 49% |
| 3 Years: | 61% |
| 1 Year: | 15% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 70% |
Last Updated: September 5, 2025, 1:55 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 57 | 144 | 65 | 71 | 29 | 41 | 50 | 32 | 45 | 52 | 56 | 70 |
| Inventory Days | 42 | 103 | 69 | 63 | 27 | 36 | 25 | 41 | 60 | 26 | 43 | 47 |
| Days Payable | 113 | 301 | 172 | 260 | 174 | 209 | 253 | 221 | 218 | 179 | 196 | 172 |
| Cash Conversion Cycle | -14 | -55 | -38 | -125 | -118 | -131 | -177 | -148 | -113 | -101 | -96 | -55 |
| Working Capital Days | -44 | -140 | -123 | -185 | -277 | -254 | -236 | -251 | -153 | -152 | -37 | 4 |
| ROCE % | 4% | 12% | 57% | -1% | 26% | 31% | 27% | 46% | 21% | 61% | 37% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 9.32 | 17.10 | -3.18 | 25.29 | -5.04 |
| Diluted EPS (Rs.) | 8.98 | 16.89 | -3.18 | 25.21 | -5.04 |
| Cash EPS (Rs.) | 13.38 | 21.07 | 0.60 | 28.45 | -1.14 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 18.09 | 8.53 | -10.03 | -7.17 | -62.46 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 18.09 | 8.53 | -10.03 | -7.17 | -62.46 |
| Revenue From Operations / Share (Rs.) | 182.94 | 175.79 | 152.77 | 156.49 | 156.91 |
| PBDIT / Share (Rs.) | 24.35 | 22.29 | 7.36 | 11.27 | 8.16 |
| PBIT / Share (Rs.) | 20.29 | 18.31 | 3.58 | 7.77 | 4.26 |
| PBT / Share (Rs.) | 9.02 | 17.20 | -3.15 | 24.84 | -4.96 |
| Net Profit / Share (Rs.) | 9.32 | 17.09 | -3.18 | 24.94 | -5.04 |
| NP After MI And SOA / Share (Rs.) | 9.32 | 17.09 | -3.18 | 24.94 | -5.04 |
| PBDIT Margin (%) | 13.31 | 12.67 | 4.82 | 7.20 | 5.20 |
| PBIT Margin (%) | 11.09 | 10.41 | 2.34 | 4.96 | 2.71 |
| PBT Margin (%) | 4.92 | 9.78 | -2.05 | 15.87 | -3.16 |
| Net Profit Margin (%) | 5.09 | 9.72 | -2.08 | 15.93 | -3.21 |
| NP After MI And SOA Margin (%) | 5.09 | 9.72 | -2.08 | 15.93 | -3.21 |
| Return on Networth / Equity (%) | 51.50 | 200.26 | 0.00 | -347.88 | 0.00 |
| Return on Capital Employeed (%) | 27.78 | 46.34 | -70.89 | -351.22 | -16.12 |
| Return On Assets (%) | 7.37 | 16.29 | -3.42 | 23.10 | -4.35 |
| Long Term Debt / Equity (X) | 2.70 | 2.93 | 0.00 | 0.00 | -0.46 |
| Total Debt / Equity (X) | 2.92 | 3.94 | -1.95 | -2.86 | -0.56 |
| Asset Turnover Ratio (%) | 1.58 | 1.78 | 1.52 | 1.60 | 1.39 |
| Current Ratio (X) | 1.11 | 0.74 | 0.38 | 0.48 | 0.28 |
| Quick Ratio (X) | 0.89 | 0.57 | 0.31 | 0.34 | 0.21 |
| Inventory Turnover Ratio (X) | 16.27 | 9.97 | 7.18 | 8.18 | 11.52 |
| Interest Coverage Ratio (X) | 2.16 | 2.50 | 1.13 | 1.79 | 0.88 |
| Interest Coverage Ratio (Post Tax) (X) | 1.83 | 2.04 | 0.54 | 1.25 | 0.45 |
| Enterprise Value (Cr.) | 929.36 | 581.65 | 182.26 | 319.37 | 284.21 |
| EV / Net Operating Revenue (X) | 1.55 | 1.01 | 0.36 | 0.62 | 0.72 |
| EV / EBITDA (X) | 11.64 | 7.97 | 7.57 | 8.67 | 13.92 |
| MarketCap / Net Operating Revenue (X) | 1.28 | 0.82 | 0.24 | 0.54 | 0.52 |
| Price / BV (X) | 12.97 | 17.09 | -3.72 | -11.86 | -1.33 |
| Price / Net Operating Revenue (X) | 1.28 | 0.82 | 0.24 | 0.54 | 0.52 |
| EarningsYield | 0.03 | 0.11 | -0.08 | 0.29 | -0.06 |
After reviewing the key financial ratios for Wanbury Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 9.32. This value is within the healthy range. It has decreased from 17.10 (Mar 24) to 9.32, marking a decrease of 7.78.
- For Diluted EPS (Rs.), as of Mar 25, the value is 8.98. This value is within the healthy range. It has decreased from 16.89 (Mar 24) to 8.98, marking a decrease of 7.91.
- For Cash EPS (Rs.), as of Mar 25, the value is 13.38. This value is within the healthy range. It has decreased from 21.07 (Mar 24) to 13.38, marking a decrease of 7.69.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 18.09. It has increased from 8.53 (Mar 24) to 18.09, marking an increase of 9.56.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 18.09. It has increased from 8.53 (Mar 24) to 18.09, marking an increase of 9.56.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 182.94. It has increased from 175.79 (Mar 24) to 182.94, marking an increase of 7.15.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 24.35. This value is within the healthy range. It has increased from 22.29 (Mar 24) to 24.35, marking an increase of 2.06.
- For PBIT / Share (Rs.), as of Mar 25, the value is 20.29. This value is within the healthy range. It has increased from 18.31 (Mar 24) to 20.29, marking an increase of 1.98.
- For PBT / Share (Rs.), as of Mar 25, the value is 9.02. This value is within the healthy range. It has decreased from 17.20 (Mar 24) to 9.02, marking a decrease of 8.18.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 9.32. This value is within the healthy range. It has decreased from 17.09 (Mar 24) to 9.32, marking a decrease of 7.77.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 9.32. This value is within the healthy range. It has decreased from 17.09 (Mar 24) to 9.32, marking a decrease of 7.77.
- For PBDIT Margin (%), as of Mar 25, the value is 13.31. This value is within the healthy range. It has increased from 12.67 (Mar 24) to 13.31, marking an increase of 0.64.
- For PBIT Margin (%), as of Mar 25, the value is 11.09. This value is within the healthy range. It has increased from 10.41 (Mar 24) to 11.09, marking an increase of 0.68.
- For PBT Margin (%), as of Mar 25, the value is 4.92. This value is below the healthy minimum of 10. It has decreased from 9.78 (Mar 24) to 4.92, marking a decrease of 4.86.
- For Net Profit Margin (%), as of Mar 25, the value is 5.09. This value is within the healthy range. It has decreased from 9.72 (Mar 24) to 5.09, marking a decrease of 4.63.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 5.09. This value is below the healthy minimum of 8. It has decreased from 9.72 (Mar 24) to 5.09, marking a decrease of 4.63.
- For Return on Networth / Equity (%), as of Mar 25, the value is 51.50. This value is within the healthy range. It has decreased from 200.26 (Mar 24) to 51.50, marking a decrease of 148.76.
- For Return on Capital Employeed (%), as of Mar 25, the value is 27.78. This value is within the healthy range. It has decreased from 46.34 (Mar 24) to 27.78, marking a decrease of 18.56.
- For Return On Assets (%), as of Mar 25, the value is 7.37. This value is within the healthy range. It has decreased from 16.29 (Mar 24) to 7.37, marking a decrease of 8.92.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 2.70. This value exceeds the healthy maximum of 1. It has decreased from 2.93 (Mar 24) to 2.70, marking a decrease of 0.23.
- For Total Debt / Equity (X), as of Mar 25, the value is 2.92. This value exceeds the healthy maximum of 1. It has decreased from 3.94 (Mar 24) to 2.92, marking a decrease of 1.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.58. It has decreased from 1.78 (Mar 24) to 1.58, marking a decrease of 0.20.
- For Current Ratio (X), as of Mar 25, the value is 1.11. This value is below the healthy minimum of 1.5. It has increased from 0.74 (Mar 24) to 1.11, marking an increase of 0.37.
- For Quick Ratio (X), as of Mar 25, the value is 0.89. This value is below the healthy minimum of 1. It has increased from 0.57 (Mar 24) to 0.89, marking an increase of 0.32.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 16.27. This value exceeds the healthy maximum of 8. It has increased from 9.97 (Mar 24) to 16.27, marking an increase of 6.30.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.16. This value is below the healthy minimum of 3. It has decreased from 2.50 (Mar 24) to 2.16, marking a decrease of 0.34.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.83. This value is below the healthy minimum of 3. It has decreased from 2.04 (Mar 24) to 1.83, marking a decrease of 0.21.
- For Enterprise Value (Cr.), as of Mar 25, the value is 929.36. It has increased from 581.65 (Mar 24) to 929.36, marking an increase of 347.71.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.55. This value is within the healthy range. It has increased from 1.01 (Mar 24) to 1.55, marking an increase of 0.54.
- For EV / EBITDA (X), as of Mar 25, the value is 11.64. This value is within the healthy range. It has increased from 7.97 (Mar 24) to 11.64, marking an increase of 3.67.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.28. This value is within the healthy range. It has increased from 0.82 (Mar 24) to 1.28, marking an increase of 0.46.
- For Price / BV (X), as of Mar 25, the value is 12.97. This value exceeds the healthy maximum of 3. It has decreased from 17.09 (Mar 24) to 12.97, marking a decrease of 4.12.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.28. This value is within the healthy range. It has increased from 0.82 (Mar 24) to 1.28, marking an increase of 0.46.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.11 (Mar 24) to 0.03, marking a decrease of 0.08.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Wanbury Ltd:
- Net Profit Margin: 5.09%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 27.78% (Industry Average ROCE: 16.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 51.5% (Industry Average ROE: 14.47%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.83
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.89
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 18.7 (Industry average Stock P/E: 43.73)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 2.92
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 5.09%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | BSEL Tech Park, B-Wing, 10th Floor, Sector 30-A, New Mumbai Maharashtra 400703 | cs@wanbury.com http://www.wanbury.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. K Chandran | Whole Time Director |
| Mr. Mohan Kumar Rayana | Whole Time Director |
| Ms. Anupama Vaidya | Ind. Non-Executive Woman Director |
| Mr. Mridul Sumanlal Mehta | Ind. Non-Executive Director |
| Mr. P V Sankar Dass | Ind. Non-Executive Director |
| Mr. Manojkumar K Gursahani | Ind. Non-Executive Director |